Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

BIOCRYST PHARMACEUTICALS INC Durham NC 27703 USA

UEI: SLED_F5BF99914C4A1805

BIOCRYST PHARMACEUTICALS INC Durham NC 27703 USA is a federal contractor, registered under UEI SLED_F5BF99914C4A1805. It has been awarded $69,388,370 across 1 federal contract. Primary work spans Pharmaceutical Preparation Manufacturing. Top awarding agencies include Aspr/orm-Sns.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_F5BF99914C4A1805

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Aspr/orm-Sns$69.4M100%

Awards by NAICS

325412 - Pharmaceutical Preparation Manufacturing$69.4M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in BIOCRYST PHARMACEUTICALS INC Durham NC 27703 USA's top NAICS codes and agencies

ZINC OXIDE OINTMENTThe contract solicitation seeks zinc oxide ointment under NSN 6505-00-150-1990 with a requested quantity of five units, issued by the Defense Logistics Agency within the Department of Defense. The solicitation, identified by number SPE2DP-26-T-4279, was posted on July 26, 2026, and requires responses no later than August 3, 2026, with all deliveries expected to fulfill federal procurement requirements. No specific set-aside provisions or NAICS codes are designated, indicating open competition among qualified suppliers. The place of performance and point of contact details are not provided, and all further inquiries must be directed through the official DIBBS portal linked in the posting.

Defense Logistics Agency

POSTED

about 7 hours ago

DEADLINE

Liquid Amies Transport Swab (ESWAB) SupplyThe contract is for the supply of ESWAB, Liquid Amies transport swabs with part number 480CFA, intended for the collection and transport of clinical specimens. This subcontract is issued under the Health and Human Services Commission in Texas and aligns with NAICS code 325412, indicating classification within pharmaceutical and medicine manufacturing. The solicitation was posted on July 24, 2026, with a response deadline set for August 18, 2026, at 4:30 PM. The swabs are critical for maintaining specimen integrity during transit and must meet specific clinical standards for accuracy and reliability. While the place of performance and point of contact details are not specified, the contract is accessible through the Texas SmartBuy portal for further procurement information.

Health and Human Services Commission

POSTED

DEADLINE

Radiopharmaceutical Manufacturing and RadiosynthesisThe contract outlines the GMP-compliant manufacturing of critical radiopharmaceuticals including Ga-68 DOTATATE, FDG, and Tc-99m based agents, requiring strict adherence to quality control protocols and regulatory standards throughout all production phases. The work must be performed at a facility in New Orleans with a zip code of 70119 and must include robust emergency continuity plans to ensure uninterrupted supply, particularly for time-sensitive diagnostic agents. Production processes must meet all applicable FDA and nuclear regulatory requirements with full documentation and traceability from raw materials to final product release. This is a subcontract under the Department of Veterans Affairs 256-NETWORK Contract Office 16, with a solicitation response deadline of August 8, 2026, and a posted date of July 24, 2026. The North American Industry Classification System code 325412 indicates a focus on pharmaceutical preparation manufacturing. The successful offeror must demonstrate proven capability in radiopharmaceutical radiosynthesis, validated quality assurance systems, and capacity to handle the unique logistical and safety challenges of radioisotope production. Continuous operational readiness and compliance with nuclear safety and transportation regulations are essential requirements.

256-NETWORK Contract Office 16 (36C256)

POSTED

DEADLINE

cDNA Clone & Molecular Biology SupplyThe contract pertains to the supply of cDNA clones encoding engineered antibody sequences for preclinical development, encompassing full molecular biology services from vector design through cloning and rigorous sequence validation. The work is required to deliver high-quality, accurately engineered genetic constructs that meet precise specifications for use in advancing therapeutic antibody candidates, ensuring reliability and reproducibility in downstream preclinical applications. All deliverables must be fully characterized and validated to confirm sequence fidelity and functional integrity. The solicitation, issued under the National Institutes of Health Office of Laboratory Animal Welfare within the Department of Health and Human Services, is a subcontract with a place of performance in Bethesda, Maryland, and carries the NAICS code 325412 for biological product manufacturing. Interested parties must submit responses by August 3, 2026, and the opportunity is open without specific set-aside classifications. The technical scope demands expertise in molecular cloning, antibody engineering, and quality control, with expectations for timely delivery and strict adherence to validated protocols to support rigorous preclinical timelines.

National Institutes Of Health Olao

POSTED

DEADLINE

Reagents and Consumables Supply for Microbiology TestingThe contract entails the ongoing supply of FDA-approved reagents, culture media, and consumables specifically designed for use with a microbiological identification and antimicrobial susceptibility testing system. All provided materials must comply with strict shelf-life requirements to ensure reliability and accuracy in diagnostic testing, and the supplier is obligated to support emergency deliveries to maintain uninterrupted laboratory operations. The work is to be performed at a designated location in Palo Alto, California, with all goods meeting federal regulatory standards for clinical diagnostic use. The contract is structured as a subcontract under the Department of Veterans Affairs through the 261-NETWORK Contract Office 21, and the North American Industry Classification System code 325412 indicates that it falls under pharmaceutical and medicine manufacturing. Bids are due by July 31, 2026, with the opportunity publicly posted on July 24, 2026, allowing qualified vendors to respond within the seven-day window.

261-NETWORK Contract Office 21 (36C261)

POSTED

DEADLINE

Radiopharmaceutical 5 yearThe U.S. Department of Veterans Affairs through the 256-NETWORK Contract Office 16 is conducting a sources sought synopsis to identify qualified vendors capable of providing radiopharmaceuticals to the Southeast Louisiana Veterans Health Care System in New Orleans, Louisiana. This is not a solicitation but a market research initiative to assess industry capabilities, business size classifications, and socioeconomic qualifications under NAICS code 325412, which has a size standard of 1,300 employees. Interested parties must submit a capability statement of five pages or less detailing their experience supplying radiopharmaceuticals to government or private medical facilities, including an authorized letter permitting such services. Responses must also include detailed information on business size, certification status under programs such as SDVOSB, VOSB, 8(a), HubZone, or woman-owned small business, UEI number, and SAM.gov registration status, with emphasis that future awards require active SAM registration and SBA certification for socioeconomic preferences. All submissions must be emailed to Veronica Maskell at veronica.maskell@va.gov with the subject line “Radiopharmaceuticals” no later than 2:00 PM CST on August 8, 2026. The response must not request a solicitation, as none currently exists; any future contract opportunity will be separately announced on GSA eBUY or Contract Opportunities, and vendors must respond to that formal solicitation to be considered for award. The Government will use responses to inform acquisition strategy and determine whether to proceed with a formal procurement. Proprietary information submitted will be protected in accordance with FAR 15.201(e), and respondents bear all costs associated with their submission. The place of performance is specified as New Orleans, LA, and the contract office is based in Ridgeland, MS, with the posting dated July 24, 2026. Failure to provide all requested information may result in the response being deemed inadequate for planning purposes.

256-NETWORK Contract Office 16 (36C256)

POSTED

DEADLINE

Chemical Agent Detector Refill Kit ManufacturingThe contract pertains to the manufacture of reactive chemical refill kits designed for use in military chemical agent detectors, encompassing the full scope of formulation, assembly, and packaging processes under strict hazardous material regulations. The work must adhere to established safety and compliance standards applicable to the handling and processing of chemically reactive substances, ensuring the kits are both effective and safe for deployment in military operations. The production environment must be certified and controlled to prevent contamination and to meet government-mandated protocols for hazardous goods. The subcontract is issued under the NAICS code 325412, indicating a focus on pharmaceutical and chemical manufacturing, and is managed by the Electrical Devices Division within the Department of Defense. Performance is required at an FPO address with ZIP code 96683, suggesting logistical coordination across military or overseas locations. The solicitation was posted on July 23, 2026, with proposals due by August 3, 2026, allowing a limited window for qualified vendors to respond. The contract does not specify a set-aside classification, and no point of contact information is provided in the solicitation, requiring potential bidders to navigate the DIBBS platform directly for further details.

ELECTRICAL DEVICES DIV

POSTED

DEADLINE

TEST STRIPS AND COLORThe contract specifies the procurement of urine test strips and color charts capable of detecting bilirubin, blood, glucose, ketone, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen, each packaged in bottles of 100 strips per unit, with a total quantity of two units required. The items must comply with stringent technical and quality requirements referenced from the DLA Master List of Technical and Quality Requirements and are subject to medical packaging standards, including compliance with Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must ensure protection against damage and safe delivery via common carriers at the lowest cost, with all labels clearly displaying the date of manufacture, expiration date, contract number, and lot number in accordance with MMS1C guidelines. A shelf-life requirement of 18 months is mandatory and non-extendable, with no more than two months allowed to have elapsed between the date of manufacture and the date of delivery to the government. The items are classified as a TYPE I (CODE K) item under the shelf-life specification, and all labeling must conform to the latest revision of MMS1C. The solicitation number is SPE2DS-26-T-263E, issued on July 23, 2026, with responses due by July 29, 2026, and delivery required within five days of award. The contracting office is under the Department of Defense’s Medical Supply Chain, with Mary-Kathryn Donahue designated as the primary point of contact. The NSN is 6550-01-221-5400, and the NAICS code is 325412, identifying the industry as medical and surgical instrument manufacturing.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

ERYTHROMYCIN OPHTHALMIErythromycin Ophthalmic Ointment, USP, is a sterile topical medication containing 5 mg of erythromycin per gram in a base of mineral oil and white petrolatum, formulated for ophthalmic use as an RX-only product. Each unit is packaged in single-dose tubes containing 3.5 grams of ointment, with a unit of issue consisting of 24 tubes per package. The product has a total shelf life of 36 months, and upon receipt by the first government activity, it must have a minimum of 31 months of remaining shelf life. Storage requirements specify controlled room temperature between 15°C and 30°C (59°F–86°F), with protection from excessive heat and freezing. All packaging and labeling must strictly conform to Medical Marking Standard No. 1, superseding MIL-STD-129, and commercial packaging must comply with ASTM D3951 unless overridden by DLA’s Master List of Technical and Quality Requirements. The manufacturer is PADAGIS US LLC with NDC 00574-4024-39, and the NSN is 6505-01-189-7090. The contract requires delivery of one package (24 tubes) to Fort Bragg, North Carolina, within 20 days of issuance, with FOB destination and zero tolerance for quantity variance. Delivery must be made via traceable freight methods, excluding parcel post, and packaging must meet all DLA procurement standards including palletization and hazardous material handling per FED-STD-313 where applicable. The item falls under a Type I (Code Q) shelf-life category with a non-extendable 36-month lifespan. The contracting official must submit a referral via EBS to confirm product compliance with FDA regulations, including manufacturer and part number details. The solicitation, issued under SPE2DP-26-T-4260, was posted on July 23, 2026, with a response deadline of July 29, 2026, and the required delivery date is July 14, 2026. All documentation, labeling, and marking must align with DLA’s current technical and quality requirements, and the point of contact for inquiries is James McCullough.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

LORATADINE TABLETSLoratadine tablets 10 mg are being procured in quantities of 2 business units, with each unit containing 500 tablets, for a total of 1,000 tablets under contract SPE2DP-26-T-4248. The product must comply with all technical and quality requirements referenced in the DLA Master List of Technical and Quality Requirements, including packaging and marking standards specified in Medical Marking Standard No. 1, which replaces MIL-STD-129. Packaging must be commercial-grade, with each unit sealed in a container that protects against damage and breakage, and shipped in exterior containers suitable for safe delivery via common carrier at the lowest cost to the destination point. The item is regulated by the FDA and requires storage between 20°C and 25°C (68°F to 77°F), protected from excessive moisture. It has a non-extendable shelf life of 36 months, classified as a TYPE I (CODE Q) item under DLA shelf-life requirements. The manufacturer is OHM Laboratories Inc. with NDC 51660-0526-05, and the distributor is AmerisourceBergen Drug Corp. Delivery is FOB destination within 20 days of contract award with zero tolerance for quantity variance, and inspection and acceptance occur at the delivery point. The NSN is 6505-01-524-9179, and all markings must adhere to the latest MMS No. 1 guidelines available through DLA Troop Support. The contracting official must submit a referral in EBS with manufacturer and bidder details prior to award.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DEXAMETHASONE TABLETSThe contract pertains to the procurement of Dexamethasone Tablets, USP, 0.5 mg, in unit dose packaging under the National Stock Number 6505-01-045-0451, with a total quantity of 2 packaging groups, each equivalent to 100 tablets. The supplier must adhere to strict packaging and labeling requirements as defined by Medical Marking Standard No. 1, which supersedes MIL-STD-129, and all units must be sealed in protective containers to ensure integrity during shipment. The product, manufactured by Roxane Labs or Hikma Pharmaceuticals USA Inc. under NDC 00054-8179-25, is regulated by the FDA and requires confirmation via EBS referral. It carries a non-extendable shelf life of 36 months and must be marked in full compliance with the latest Medical Marking Standard. Delivery is required FOB destination within five days of contract award, with zero variance allowed in quantity, and inspection and acceptance occur at the destination point. The solicitation is issued under SPE2DP-26-T-4266, with a response deadline of July 29, 2026, and the sole point of contact is James Foggie at DLA Troop Support, with performance directed to Fort Bragg, NC, 28310.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TUBE, EXTENSION, INJEThe item is a 3-way stopcock extension set with 60-inch small bore tubing featuring a male luer lock connection, designed for injection procedures, with a priming volume of 1.3 mL and packaged in quantities of 25 units per package. The product is identified by NSN 6515-01-550-8492 and is being procured under solicitation SPE2DS-26-T-268C, with a response deadline of July 29, 2026, and a delivery requirement of 20 days after award. The specification includes technical and quality requirements referenced in the DLA Master List, and packaging must comply with DLA standards, including the removal of government identification from non-accepted supplies. The contract is managed by the Department of Defense through the Medical Supply Chain MD Surg FSF office, with performance required at Fort Bliss, Texas, and point of contact information provided for inquiries.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

RINGER'S INJECTION, LACRINGER'S INJECTION LACTATED USP in 1000 mL units, packaged 12 per pack (1 PG), is procured under contract SPE2DP-26-T-4258 with a total quantity of 21 packs to be delivered within 20 days FOB destination. The product is regulated by the FDA and carries a non-extendable shelf life of 30 months as a TYPE I (CODE P) item. Packaging must comply with Medical Marking Standard No. 1, replacing all prior references to MIL-STD-129, and must ensure protection from damage and breakage during transit. Units must be packed in commercial exterior shipping containers suitable for safe delivery at the lowest carrier rate, with labeling and marking strictly following the latest version of MMS No. 1. The product must be stored at room temperature (25°C), with brief exposure up to 40°C permitted without adverse effects, and must be protected from freezing and excessive heat. The manufacturer is B. BROWN MEDICAL INC with NDC number 00264-7750-00 and part number L7500. Inspection and acceptance occur at the delivery point with zero variance allowed in quantity. All technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements, with applicable revisions controlled by the solicitation or award date. Government identification must be removed from non-accepted supplies per RQ011, and procurement is subject to covered defense information provisions. Delivery is to Fort Bragg, NC, with primary point of contact Timothy McCauley at DLA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ALBUMIN HUMANALBUMIN HUMAN USP 25% in 50 mL vials is specified for intravenous use only, with a concentration of 25% volume to volume, and is heat treated with included administration accessories such as 18 or 20 gauge needles. Each unit must be free of turbidity and stored at room temperature, with no freezing allowed. The product has a non-extendable shelf life of 36 months and is classified as a TYPE I (CODE Q) item under shelf-life requirements. It is regulated by the FDA, and buyers must ensure proper referral through EBS to confirm bidder and manufacturer details, including NDC numbers for KEDRION BIOPHARMA INC and GRIFOLS USA LLC. Packaging must comply with Commercial standards as specified in the procurement document, conforming to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and must be contained in sealed, protective unit containers within suitable commercial shipping containers to ensure safe, low-cost delivery to the destination point. All units must be marked and packaged according to MIL-STD-2073-1E, and the material is subject to RD003 covered defense information provisions. The contract calls for a delivery of exactly 10 packs, each containing one 50 mL vial, totaling 500 mL, to be delivered within five days FOB destination with zero variance allowed. Inspection and acceptance occur at the destination. The solicitation number is SPE2DP-26-T-4249, issued by the Department of Defense’s Medical Supply Chain, with a response deadline of July 29, 2026, and performance is designated for Fort Bragg, NC.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

WATER FOR INJECTIONThe contract specifies the procurement of 10 packages of Water for Injection, Sterile, USP, each package containing 25 sterile 20 mL vials with flip-top closures, for a total of 250 vials. The product must comply with USP standards and be labeled in accordance with the latest Medical Marking Standard No. 1, with packaging conforming to MIL-STD-2073-1E. Storage requirements mandate controlled room temperature between 20 and 25 degrees Celsius, and the item has a non-extendable shelf life of 24 months as per RS016 and RS001 for a Type I (Code M) item. The delivery is FOB destination within 20 days of contract award with zero variance allowed in quantity, and inspection and acceptance occur at the destination. The item is regulated by the FDA, and buyers must submit a referral through EBS including manufacturer and bidder details. Only two approved manufacturers are listed: Hospira Worldwide LLC with NDC 00409-4887-20 and Fresenius Kabi, LLC with NDC 63323-0185-20. The contract is issued under solicitation SPE2DP-26-T-4261, with a response deadline of July 29, 2026, and the NSN is 6505-00-582-5079. All technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements, and provisions for removal of government identification from non-accepted supplies and potential covered defense information apply.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TOLNAFTATE POWDER, UThe contract specifies the procurement of TOLNAFTATE POWDER USP 1% in 45 gram units, identified by NSN 6505014807897 and NDC 57896-0199-45, supplied by GERI-CARE PHARMACEUTICALS CORP. The item is classified as a TYPE I (CODE Q) medical product with a non-extendable shelf life of 36 months and must be packaged in compliance with the DLA Master List of Technical and Quality Requirements, superseding all other standards including ASTM D3951 and MIL-STD-129. Each unit must be sealed in a protective container and shipped in commercial exterior packages suitable for safe delivery via common carrier at the lowest cost, marked in accordance with Medical Marking Standard No. 1, which replaces all prior military marking requirements. The unit of issue is BT, where one BT equals 45 grams, and each shipment must adhere to strict palletization and labeling guidelines outlined in RP001 and other referenced DLA technical directives. The contract includes three separate line items totaling 28 BT (1,260 grams), with delivery deadlines of July 23, 2026, for 24 BT destined to FPO AP 96694, July 27, 2026, for 3 BT to VILSECK, Germany, and one BT to an unspecified location. All deliveries are FOB destination, with zero variance allowed in quantity, inspection and acceptance occurring upon arrival. Shipment must occur via the fastest traceable means, explicitly prohibiting parcel post, and must comply with hazardous material handling requirements per FED-STD-313 and IP025 if applicable. The contract is issued under solicitation SPE2DP-26-T-4256, with a five-day delivery window, and all packaging and labeling requirements must reflect the latest DLA medical standards, ensuring full traceability, regulatory compliance, and readiness for military medical use.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

SODIUM CHLORIDE INJECTSodium Chloride Injection 0.9% in 100 mL fill, 150 mL plastic containers, is procured in units of 64 containers per package (1 PG), with a total quantity of one package required under contract SPE2DP-26-T-4269. The product is manufactured by B. Braun Medical Inc., identified by NDC 00264-1800-32 and part number S8004-5264, and is regulated by the FDA. It has a non-extendable shelf life of 15 months from the date of manufacture and must be labeled with the NSN 6505013308924, manufacturer details, CAGE code, manufacture and expiration dates, and contract/lot number in strict compliance with Medical Marking Standard No. 1A dated February 4, 2013, which supersedes MIL-STD-129. Packaging must be commercial grade, sealed to protect contents from damage, and shipped in exterior containers ensuring safe delivery at the lowest cost to the destination point specified in the contract. Delivery is required within five days FOB destination with zero variance allowed on quantity. Inspection and acceptance occur at the point of delivery. The item is subject to DLA packaging and quality requirements as defined in their Master List, and all labeling and marking must conform to the latest version of MMS No. 1, available through DLA’s official website. Storage must be at room temperature (25°C) and exposure to excessive heat must be avoided.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

SODIUM CHLORIDE INJECTSodium Chloride 0.9% Injection, USP in 500 mL units, packaged 24 per case, is being procured under solicitation SPE2DP-26-T-4264 with a requirement for two cases totaling 48 units. The product is regulated by the FDA and must comply with all applicable medical standards including Medical Marking Standard No. 1, which supersedes MIL-STD-129, and must be packaged in sealed unit containers that protect against damage and shipped in commercial exterior containers suitable for safe delivery at the lowest cost to the designated destination. The item has a non-extendable shelf life of 24 months and is classified as a Type I (Code M) item under DLA’s shelf-life requirements. Strict prohibitions against intentional mercury or mercury-containing compounds apply, with limited exceptions for functional uses in batteries, lighting, instruments, sensors, weapon systems, and specific chemical reagents as defined by NAVSEA. Packaging and marking must adhere to MIL-STD-2073-1E and include compliant labeling with the assigned NSN 6505-01-330-6268. Delivery is required FOB destination within 20 days with no variance allowed in quantity. Approved manufacturers include Cardinal Health, Baxter Healthcare Corp, McKesson, B. Braun Medical Inc, ICU Medical Sales, and Tribalco LLC, each with designated part numbers and NDCs. The contract mandates referral through EBS to confirm product eligibility and compliance, with full technical and quality requirements governed by the DLA Master List as of the solicitation issue date. The solicitation closed on July 29, 2026, and is managed by the Department of Defense's Medical Supply Chain Pharmacy FSA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE